Milestone Scientific Inc (MLSS)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$0.40-9.70%
Close 2026-09-09 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Milestone is improving cash flow from operations, up $313K from last quarter. It is growing revenue about 17% next year. The company is working on deals with Innovest S.p.A. to grow. New board members may help stabilize management.
Milestone is still losing money and has fragile quality. Revenue missed estimates recently. The stock is down 27% from its high. Management changes and legal issues add risk.
The market expects about 17% revenue growth next year. Our fair value is near $0.91, close to the current price. We see risk from ongoing losses and weak cash flow.
Breaks if: cash from operations falls below zero next year
Breaks if: Further key management departures or instability occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is weakened, as recent financial performance has dropped significantly, indicating potential volatility ahead.
The market seems to have priced in a low level of execution quality, reflecting a justified valuation despite the company's fragile earnings situation. There is a divergence in expectations, with a notable premium compared to peers.
Fundamentals are likely to remain under pressure due to ongoing negative net income and mixed results from capital allocation efforts. Recent revenue growth is positive, but the overall financial health appears fragile.
The long-term thesis hinges on external factors such as the performance of sector bellwethers and the company's ability to execute its strategic priorities effectively. Any shifts in the healthcare sector's momentum could significantly impact MLSS.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates the reason to own it has weakened. The market backdrop has also shifted, with the XLC and XLP sectors deteriorating, creating headwinds.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue growth falls below 10% next year
Continue strategic M&A activities with Innovest S.p.A. to enhance market position.
Over the next 1 to 3 years, MLSS will need to navigate high risks and fragile earnings while trying to capitalize on sector trends. Not investment advice.